Zoetis fell 6% on cut full-year guidance, ResMed slid 5% after price target reductions, and Seagate dropped nearly 5% Monday — a reminder that individual guidance matters even in a bullish market.
Even as broader markets pointed higher Monday morning on softer jobs data and falling yields (covered in our companion post), three individual names told a very different story. Zoetis, ResMed, and Seagate Technology all declined sharply, each for its own company-specific reason — a reminder that guidance quality continues to matter enormously even in an otherwise constructive market environment.
Zoetis: a direct guidance cut
Zoetis (NYSE: ZTS) fell 5.97% after the animal health company cut its full-year 2026 revenue and EPS guidance. Unlike some of the more nuanced "beat but still fell" reactions we've tracked throughout this earnings season, Zoetis's decline reflects a direct, unambiguous downward revision to the company's own outlook — the kind of clear-cut guidance cut that tends to move a stock predictably regardless of broader market conditions.
ResMed: price targets trimmed after otherwise solid results
ResMed (NYSE: RMD) declined 5.06% following slightly lower analyst price targets issued after the company's recent second-quarter results. This reaction fits a pattern we've seen repeatedly this earnings season: even when quarterly results themselves aren't disastrous, analysts trimming forward price targets can weigh on a stock independently, particularly if the revisions suggest slowing longer-term growth assumptions.
Seagate: continued pressure in storage
Seagate Technology (NASDAQ: STX) fell 4.71%, extending a difficult stretch for storage-sector names. As we covered in our earlier post on SanDisk's dramatic post-earnings decline despite 372% revenue growth, memory and storage stocks have shown particular sensitivity to forward guidance this earnings season, with the sector's dramatic 2026 gains leaving little room for anything less than fully reassuring commentary.
A useful counterpoint to Monday's broader optimism
These three declines are worth holding alongside the genuinely positive macro backdrop covered elsewhere in today's coverage — Shopify's 17% AI-driven surge, easing Fed rate-hike odds, and Tom Lee's bullish S&P 500 call. Monday's session shows that even in a market with real reasons for optimism, company-specific guidance and analyst revisions can still produce sharp, isolated declines that have little to do with the broader index's direction.
What investors should watch
- Whether Zoetis's guidance cut reflects a company-specific issue or signals broader softness in the animal health sector
- Further analyst commentary on ResMed, to see whether more price target revisions follow
- Whether Seagate's decline is part of a broader storage-sector pattern, echoing the SanDisk reaction covered in our earlier post
- How each stock performs relative to the broader market as this week's inflation data (covered in our companion post) unfolds
Bottom line
Monday's declines in Zoetis, ResMed, and Seagate serve as a useful reminder that broad market optimism doesn't protect individual stocks from company-specific guidance disappointments. Even amid a session defined by falling rate-hike odds and a Shopify-driven AI success story, these three names show that stock-picking fundamentals still matter as much as ever.
This post is based on reporting from The Morning Bull via Yahoo Finance as of August 10, 2026. This content is for informational purposes only and does not constitute investment advice.
Post a Comment